Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Busch, R.
Right arrow Articles by Mellins, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Busch, R.
Right arrow Articles by Mellins, E. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 42, 27557-27564, October 16, 1998


Secondary Structure Composition and pH-dependent Conformational Changes of Soluble Recombinant HLA-DM*

Robert BuschDagger , Ziv Reich§, Dennis M. Zaller, Victor Sloanparallel , and Elizabeth D. Mellins

From the Department of Pediatrics and the § Howard Hughes Medical Institute, Stanford University, Stanford, California 94305 and  Merck Research Laboratories, Rahway, New Jersey 07065

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

HLA-DM catalyzes the release of invariant chain fragments from newly synthesized major histocompatibility complex (MHC) class II molecules, stabilizes empty class II molecules, and edits class II-associated peptides by preferentially releasing those that are loosely bound. The ability of HLA-DM to carry out these functions in vitro is pH dependent, with an optimum at pH 4.5-5.5 and poor activity at pH 7. The structural basis for these properties of HLA-DM is unknown. Sequence homology suggests that HLA-DM resembles classical, peptide-binding MHC class II molecules. In this study, we examined whether HLA-DM has a secondary structure composition consistent with an MHC fold and whether HLA-DM changes conformation between pH 5 and pH 7. Far-UV circular dichroism (CD) spectra of recombinant soluble HLA-DM (sDM) indicate that HLA-DM belongs to the alpha /beta class of proteins and structurally resembles both MHC class I and class II molecules. The CD peak around 198 nm increases upon going from neutral to endosomal pH and drops sharply upon denaturation below pH 3.5, distinguishing at least three states of sDM: the denatured state and two highly similar folded states. Fluorescence emission spectra show a slight blue-shift and a approx 20% drop in intensity at pH 5 compared with pH 7. Unfolding experiments using guanidinium chloride show that the stability of sDM is somewhat reduced but not lost at pH 5. These results indicate that sDM undergoes a pH-dependent conformational change between neutral and endosomal pH. The change seems to involve both hydrogen bonding patterns and the hydrophobic core of sDM and may contribute to the pH dependence of DM activity.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Major histocompatibility complex (MHC)1 encoded glycoproteins bind antigenic peptides and display them on the surface of antigen-presenting cells for inspection by T lymphocytes bearing alpha beta antigen receptors. MHC molecules can be divided into class I and class II molecules, which share a common tertiary fold with a characteristic peptide binding groove but differ in their domain connectivity, specificity requirements for peptide, and ability to stimulate selectively CD8+ and CD4+ lymphocytes, respectively (1). These highly polymorphic "classical" MHC molecules belong to a larger family, which includes more distantly related and less polymorphic molecules encoded in the class II and class Ib regions of the MHC and elsewhere in the genome (2). Among the functions identified for such "nonclassical" MHC molecules are antigen presentation to unconventional T cells, accessory functions in MHC class II antigen presentation, and other, unrelated functions.

Classical MHC class II molecules load peptides in endosomal compartments, and this process is regulated by at least three additional molecules: invariant chain (Ii), HLA-DM, and HLA-DO (3, 4). Ii, which lacks homology to MHC molecules, associates with class II molecules in the endoplasmic reticulum, facilitates their assembly, and targets them to endosomes. Here, Ii is degraded, leaving Ii-derived peptides in the antigen binding groove (class II-associated Ii peptides, CLIP). CLIP must be released from class II molecules to permit normal binding of endosomal peptides, a process that is accelerated by HLA-DM (5-17). In addition, DM-catalyzed peptide release is not limited to CLIP (15, 18, 19), so that distinct sets of peptides are loaded onto class II molecules in DM+ and DM- cells (20, 21). These effects do not seem to be due to any influence of HLA-DM on MHC class II trafficking (22-24). Finally, DM stabilizes class II peptide binding sites against inactivation (25, 26). The function of HLA-DO has been studied less extensively, but there is some evidence that it modulates DM function (27-29).

The intron-exon structure and promoter regions of the DMA and DMB genes that encode DM alpha beta dimers show similarities to class II alpha  and beta  chain genes (30). Both DMA and DMB cDNAs show weak sequence homology to classical class I and class II MHC molecules (31, 32). The lowest degree of homology is seen in the membrane-distal domains, which contain the antigen-binding site of classical MHC proteins. Consistent with an MHC-like fold, a Cys residue (Cys-79) in the beta 1 domain of DM, which is conserved among MHC molecules, is important for proper DM folding (33). Unlike classical class II molecules, however, no evidence for peptide binding activity of HLA-DM has been found, raising the possibility that it lacks a ligand binding groove (16, 34).

The mechanism by which DM alters peptide loading of class II molecules is starting to be elucidated. HLA-DM associates directly with MHC class II molecules (35); the most stable association seems to be with empty molecules (25, 26), but peptide-loaded molecules also may have some affinity for DM (35). DM accelerates peptide dissociation from MHC class II molecules (15-17, 36) without changing peptide specificity (37). This result suggests that DM stabilizes an "open" class II conformation without altering interactions between class II specificity pockets and side chains of the bound peptide, perhaps by breaking hydrogen bonds between class II and the peptide (38). Antibody-blocking experiments and the characterization of a HLA-DR mutant defective for DM binding suggest that a specific face of the class II molecule is involved in DM interactions (16, 24, 39). Based on hydrophobic dye binding studies, it has been proposed that the interaction involves hydrophobic sites that are buried at the DM-class II interface (40).

Peptide loading of class II molecules occurs in acidic (pH 4.5-5.5) late endosomal compartments (23, 24). Structural features of both MHC class II molecules and HLA-DM may contribute to ensuring efficient peptide loading under these conditions. In some instances, titratable side chains at the peptide-MHC class II interface may provide optimal interactions at endosomal pH (41). In addition, MHC class II molecules change conformation between pH 7 and pH 5, as shown by spectroscopy and by differential hydrophobic dye binding (42-45). The most pronounced rearrangements may occur at sites that are distant from the peptide binding groove (43); nevertheless, they are associated with accelerated peptide binding and release at low pH. Not all peptide/MHC class II combinations behave like this; examples of pH-independent peptide binding are not uncommon. Even in these cases, however, peptide binding becomes pH dependent upon adding HLA-DM (15). DM binding to class II molecules and its catalytic activity are greater at pH 4.5-5.5 than at neutral pH (15, 17, 25, 35).

Hydrophobic dye binding of HLA-DM also increases at pH 5, but the effects seem modest compared with those previously seen for classical class II molecules (28, 40).2 We therefore wished to determine the nature and extent of any changes in HLA-DM conformation between neutral and endosomal pH. Here, we have used far-ultraviolet circular dichroism and intrinsic fluorescence spectroscopy to analyze both the secondary structure composition of the lumenal domains of HLA-DM and the effect of pH on their conformation and stability.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cells-- Drosophila melanogaster-derived S2 cells expressing recombinant soluble HLA-DM (sDM) have been described (15). Briefly, expression vectors were constructed that contained truncated DMA*0101 and DMB*0101 cDNAs under the control of a metallothionein promoter. For both chains, the transmembrane regions and cytoplasmic tails were replaced by epitope tag sequences, which are recognized by the monoclonal antibodies, M2 and KT3, respectively. A similar strategy was used to generate transfectants expressing full-length DM, as well as full-length and soluble HLA-DR1, all without epitope tags. After transfection and antibiotic selection, highly expressing subclones were isolated, and expression of transfected cDNA was induced in serum-free spinner cultures by adding 1 mM CuSO4. For full-length molecules, cells were harvested after 24 h, washed in Dulbecco's phosphate-buffered saline without Ca2+/Mg2+, and stored at -80 °C; for soluble molecules, culture supernatant was harvested after 7 days.

Purification of Recombinant Molecules-- Insect cell-derived recombinant DR1 was purified by immunoaffinity chromatography as described (46). Soluble DR1 was purified similarly, except that concentrated culture supernatants were loaded onto the column and detergent was omitted. For purification of sDM, culture supernatants were centrifuged (3000 × g, 20 min), and 1 mM phenylmethylsulfonyl fluoride and 10 mM iodoacetamide were added. Filtered (<0.2 µm) supernatants were passed over a glycine-coupled CNBr-Sepharose column and an M2 immunoaffinity column (Eastman Kodak) connected in series. After washing in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, specifically bound material was eluted from the M2 column using 100 µM FLAG peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys; Eastman Kodak) in wash buffer, and the column was regenerated by alternating 20-min washes in 50 mM glycine-HCl, pH 3.5, and wash buffer. The column eluate was concentrated by centrifugal ultrafiltration (Centriprep-30 and Centricon-30, Amicon) and loaded onto a 2 × 30-cm Sephacryl S200-HR column (Amersham Pharmacia Biotech), which was eluted in phosphate-buffered saline. Fractions containing sDM dimer without contaminating proteins were pooled and again concentrated. After a buffer exchange into water, sDM was stored in aliquots at -20 °C. The final yield of pure sDM dimer was approximately 4 mg per liter of culture supernatant.

Full-length recombinant DM was affinity purified from S2 cell transformants. A previously described polyclonal antiserum raised to sDM (11323; see Ref. 33 for a description of its reactivity) was affinity purified using sDM covalently coupled to CNBr-activated Sepharose 4B (Pharmacia; 5 mg of sDM per ml of beads) and eluted using 100 mM glycine-HCl, pH 3.0. The affinity-purified immunoglobulin, in turn, was coupled to CNBr-Sepharose 4B (2 mg of IgG per ml of beads). A CHAPS (1% w/v) extract from 1010 S2 transformants was applied to the anti-DM affinity column. The column was washed with 10 mM Tris-HCl, pH 7.5, 1% CHAPS, 150 mM NaCl, and then with 10 mM Tris-HCl, pH 7.4, 1% CHAPS, 500 mM NaCl. DM was eluted with 50 mM glycine-HCl, pH 3.8, 1% CHAPS and immediately neutralized with 2 M Tris-HCl, pH 8.0. Fractions containing DM were pooled and further purified by gel filtration chromatography on a Superdex 200 column (Pharmacia). Protein was quantified by Bradford assay and by a DM-specific competitive enzyme-linked immunosorbent assay using purified sDM as a standard, and silver staining of purified full-length DM failed to detect any contaminating proteins (data not shown). The final yield was approximately 0.5 mg of full-length DM per 1010 cells.

Protein Characterization and Quantitation for Spectroscopy-- Fractions from various stages of the purifications were separated by SDS-PAGE (47). Total proteins were visualized by Coomassie Blue staining, and large amounts of protein (up to 20 µg/lane) were loaded to assess purity. Soluble DM alpha  and beta  chains were identified by immunoblotting using epitope tag-specific mAbs, using previously described protocols (15, 33). To confirm the stability of sDM heterodimers following storage, samples were rerun on a Sephacryl S200-HR column in 20 mM sodium phosphate (pH 7.0) or sodium acetate (pH 5.0) buffers containing 150 mM NaCl. Amino-terminal sequencing by Edman degradation was performed by the Stanford University Protein and Nucleic Acid Facility.

The derived amino acid sequences encoded by the sDMA and sDMB were used to calculate an extinction coefficient epsilon 280 = 79270 M-1 cm-1 in 20 mM sodium phosphate buffer, pH 6.0, 6 M guanidinium chloride (48, 49). The extinction coefficient of sDM was not affected measurably by the presence or absence of denaturant (data not shown). The calculated extinction coefficient agreed to within 3% with an empirical value derived from quantitative amino acid analysis (performed by the Stanford University Protein and Nucleic Acid Facility) and was used routinely to quantitate sDM by UV spectrophotometry.

Assay for DM-catalyzed Peptide Binding to DR1 Molecules-- DM-dependent peptide binding to DR1 was measured essentially as described (15). Briefly, 2 nM recombinant full-length or soluble HLA-DR1 was allowed to bind 1 µM N-terminally biotinylated HA307-319 peptide in the presence of varying amounts of full-length or soluble recombinant HLA-DM. After incubation in 150 mM sodium citrate/phosphate buffer, pH 5.0, containing 0.5% Nonidet P-40 at 37 °C for 1 h, HLA-DR molecules were captured on microtiter plates coated with the anti-DR monoclonal antibody, LB3.1. Bound peptide was detected using Eu3+-conjugated streptavidin, which was quantitated by time-resolved fluorescence. A standard curve was generated by serial dilution of DR1 molecules maximally loaded with the biotinylated HA307-319 peptide and fitting to a 4-parameter binding equation, which was used to convert bound fluorescence to percent occupancy.

Circular Dichroism Spectroscopy-- Far-ultraviolet circular dichroism spectra were acquired on an Aviv 62DS spectropolarimeter equipped with a thermostatted cuvette, using previously described conditions (44, 50). Samples contained 100-250 µg/ml sDM in 5 mM sodium phosphate buffer, pH 7.0, or 5 mM sodium acetate buffer, pH 5. A 1-mm path length cuvette was used, and samples were recovered after analysis and quantitated by UV absorption spectrophotometry as described above. Five CD spectra were acquired using previously described parameters (44), averaged, and smoothed using a 9-point (2.25 nm) sliding window; the buffer background was then subtracted. For pH titrations, samples were made up in appropriate mixtures of 5 mM sodium phosphate, sodium acetate, and HCl, and the pH of the mixtures was checked after each experiment. A single spectrum was acquired at each pH in 0.5-nm steps with a 5-s averaging time. Estimates for alpha -helix and beta -pleated sheet content were obtained using the program, k2d, (available at http://columba.ebi.ac.uk:8765/~andrade/k2d.html) (51, 52).

Fluorescence Spectroscopy-- Fluorescence spectra were acquired at room temperature, using a Hitachi F-4010 spectrofluorimeter with excitation at 280 nm. Samples of sDM (50-1000 nM) were prepared in filtered (0.2 µm) 20 mM sodium phosphate (pH 7) or acetate (pH 5) buffers with or without 150 mM NaCl or 6 M guanidinium chloride and analyzed in a 1 × 1-cm path length cuvette. Emission scans were performed at ambient temperature (23 °C) at 0.5 nm/s with a 2-s averaging time and 4-nm bandwidth for both excitation and emission. Background fluorescence from buffer alone was subtracted. Denaturant titrations were done in a thermostatted cuvette (25 °C) by slowly adding increasing amounts of buffered 6 M guanidinium chloride to rapidly stirred solutions containing 250 nM sDM and 20 mM phosphate (pH 7) or acetate (pH 5) buffer. In the unfolding transition region, progress of the unfolding reaction was followed by measuring fluorescence emission at 350 nm over time, or by repetitive scanning, and spectra were recorded after completion of the reaction. Reversibility was tested by diluting fully denatured samples (2 M guanidinium chloride) back to nondenaturing guanidinium chloride concentrations and following fluorescence emission at 350 nm. After correction for background and dilution effects, limiting slope corrections were applied to fluorescence intensities at 350 nm to estimate the relative amounts of native and unfolded sDM, assuming an irreversible one-step conversion from a native to an unfolded conformation.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

For spectroscopic characterization, recombinant-soluble HLA-DM (sDM) was purified from supernatants of transfected Drosophila cells, using epitope tag affinity chromatography and gel filtration (Fig. 1A). Gel filtration separated heterodimeric sDM from high molecular weight aggregates containing contaminating proteins, as shown by Coomassie Blue staining of overloaded native (data not shown) and SDS-PAGE gels (Fig. 1A). The SDS gels were overrun to resolve sDM chains as a closely spaced multiplet of bands, which were assigned as either alpha  or beta  chains by Western blotting with mAbs to the C-terminal epitope tags (Fig. 1B). Thus, all the material in sDM dimer fractions could be accounted for by sDM alpha  and beta  chains. N-terminal sequencing of sDM dimers yielded two simultaneous sequences, VPEAPTPMWPDDLQ and FVAHVESTXLLDDAG, consistent with signal sequence cleavage after residue 26 of immature DM alpha  and after residue 20 of immature DM beta , respectively (counting from the initiating Met). Note that the mature beta  chain N terminus is two residues downstream from the beginning of the beta 1 domain predicted by Kelly et al. (31). This may be due to incorrect prediction of signal sequence cleavage or limited proteolysis during or after secretion. As the N termini seemed homogeneous by sequencing and all bands resolved by SDS-PAGE contained the C-terminal epitope tags, the size heterogeneity of both chains seen by SDS-PAGE likely was a result of heterogeneous covalent modifications, such as glycosylation. By gel filtration, sDM remained an alpha beta heterodimer after storage at -20 °C, both at pH 7 (Fig. 1C) and pH 5 (data not shown). In conclusion, our sDM preparations were of sufficient purity and quality for spectroscopic analysis.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Purification of sDM for spectroscopic studies. A, separation of sDM alpha beta dimers from aggregates and contaminating proteins by Sephacryl S-200 HR chromatography. Recombinant insect cell-derived sDM was isolated by affinity chromatography on an anti-FLAG (M2) mAb column. Material eluted with FLAG peptide (M2 eluate) was concentrated and subjected to gel filtration. Aliquots of protein-containing fractions were analyzed by SDS-PAGE and Coomassie Blue staining. Aggregates containing contaminating proteins peaked in fractions 20-26 and sDM dimers in fractions 27-35. Within the dimer peak, fractions 29-34 lacked detectable contaminating proteins and were pooled for spectroscopic studies. B, identification of sDM chains. sDM was Western blotted using mAbs to alpha  chain (M2) and beta  chain (KT3) epitope tags, as well as a polyclonal rabbit antiserum raised to sDM (11323). C, stability of sDM dimer after storage. sDM stored at -20 °C was thawed and reanalyzed by gel filtration at pH 7. The migration of marker proteins is indicated by arrows.

We have shown previously that sDM catalyzes release of CLIP and a subset of other peptides from MHC class II molecules (15). sDM also promotes association of labeled peptides with class II molecules, likely by catalyzing dissociation of previously bound ligands. Micromolar sDM concentrations are required for half-maximal peptide loading, whereas other groups have reported that nanomolar concentrations of native, full-length DM purified from Epstein-Barr virus-transformed B cell lines are catalytically active (16, 17). To assess the role of the transmembrane and/or cytoplasmic domains in the interaction between DM and class II molecules, full-length and soluble, insect cell-derived DM molecules were compared for their ability to catalyze peptide loading of full-length and soluble DR1 (Fig. 2). In this experiment, between 4 and 8 µM soluble DM were required for half-maximal loading of either soluble or full-length DR1 molecules. Even though we were unable to test the activity of high concentrations of full-length DM, at low concentrations similar amounts of full-length and soluble DM were needed to load soluble DR1 molecules, suggesting that the transmembrane region and cytoplasmic tail of DM were unimportant for peptide loading of soluble DR molecules. Interestingly, when full-length DR1 was used, full-length (but not soluble) DM was active at about 200 times lower concentrations (half-maximal loading between 20 and 40 nM DM), a potency comparable with that seen for affinity-purified DM from B cell lines.3 These results showed that optimal catalytic activity required the transmembrane domains and/or cytoplasmic tails of both DM and DR1, either because these domains interact specifically during catalysis or because the transmembrane regions help to align DM with DR through interactions with detergent micelles. However, because peptide loading of soluble DR1 was not influenced by the presence or absence of the DM transmembrane region or cytoplasmic tail, these domains did not seem to be required for correct folding and activity of the extracellular domains of DM. This finding justified the use of soluble molecules for spectroscopic studies investigating the folding and conformational dynamics of DM.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Peptide loading of full-length and soluble DR molecules in the presence of full-length or soluble DM. Full-length (triangles) and soluble (circles) DR1 molecules were purified from insect cells and incubated at 2 nM with 1 µM biotinylated HA307-319 peptide in the presence of varying amounts of either full-length (filled symbols) or soluble (open symbols) DM as shown. Peptide binding was quantitated by an antibody capture assay as described under "Materials and Methods."

Far-UV CD spectroscopy was used to analyze the secondary structure composition of sDM (Fig. 3). The CD spectrum at 25 °C and pH 7.0 revealed a pronounced minimum at 218 nm and a maximum at 198 nm, placing sDM within the alpha /beta class of proteins with a significant amount of beta -pleated sheet and a moderate alpha -helical content (Fig. 3A, Table I). The spectrum changed little upon heating to 37 °C (Fig. 3B) and underwent little change up to about 50 °C (data not shown). However, further heating to 80 °C resulted in drastic changes in the far-UV CD spectrum; the heat-denatured material gave a minimum at 205 nm and a maximum at 188 nm (Fig. 3B). These spectral changes showed that sDM adopted a highly stable, folded structure at neutral pH.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Far-UV CD spectroscopic analysis of sDM. A, far-UV CD spectrum of sDM (continuous line) at pH 7 and 25 °C. Error bars represent standard deviations from three independent measurements. Shown for comparison are spectra of a recombinant soluble form of the murine class II molecule, I-Ek (dashed line; from Ref. 44), and the papain-solubilized extracellular domains of the human class I molecule, HLA-A2 (dotted line; from Ref. 50). B, far-UV CD spectrum of sDM at 25 °C (continuous line), 37 °C (dashed line), and 80 °C (dotted line).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Estimated secondary structure composition of sDM and MHC-related molecules of known structure

The qualitative features of the native sDM far-UV CD spectrum resembled those of classical MHC class I and class II proteins, but the spectra were not superimposable (Fig. 3A). The overall shape of the sDM spectrum was somewhat closer to typical class II (I-Ek) than class I (HLA-A2) CD spectra, as reflected for instance in the ratio of the 218- and 198-nm peaks and the presence of a shoulder in the 222-230-nm range. However, the intensity of this shoulder for sDM was intermediate between I-Ek and HLA-A2. The secondary structure composition of sDM, as estimated using a neural net algorithm, was within the range previously determined by crystallographic or spectroscopic analysis of a set of MHC-like proteins (Table I). The differences between the CD spectra of distantly related molecules of the MHC family might reflect differences in the details of tertiary and quaternary structure, or they could reflect non-peptide bond contributions to the far-UV CD spectrum (for discussion of such contributions, see Refs. 44 and 53). In conclusion, overall the CD properties of sDM are consistent with an MHC-like fold, but the precise tertiary structure may differ from that seen for classical MHC class I and class II proteins with peptide-binding function.

To study the effect of exposure to low pH on the conformation of sDM, CD spectra were recorded in a series of buffer mixtures ranging from pH 7.3 to pH 2.5. Fig. 4A shows far-UV CD spectra of sDM at pH 7.3, 4.8, and 2.5, recorded at room temperature. Dropping the pH from 7.3 to 4.8 resulted in a slight but reproducible increase in the intensity of the 198-nm peak of the far-UV CD spectrum, with little (if any) change in estimated secondary structure content (Table I). In particular, no changes were observed in the 222-nm region of the spectrum, indicating that helix content was not altered at endosomal pH. A further drop in pH to 2.5 resulted in drastic spectral changes; the pH 2.5 spectrum closely matched that of heat-denatured material at pH 7 (cf. Fig. 3B). This result indicated that the increase of the 198-nm peak at pH 4.8 was not due to incipient acid denaturation because a further drop in pH decreased the CD signal at this wavelength. The intensity of the 218- and 198-nm peaks was measured for a range of pH values between 2 and 8 (Fig. 4B). This analysis revealed that the CD signal at 198 nm increased in intensity between pH 7 and 5 and decreased below pH 3.5; in contrast, the 218-nm peak did not change in intensity until the pH was decreased below 3.5. Together, these observations define three spectroscopically distinct states of sDM: the denatured state (similar for both heat and acid denaturation) and two states differing in abundance between pH 7 and 5. 


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of pH on CD spectrum of sDM. A, far-UV CD spectrum of sDM at pH 7.3 (continuous line), pH 4.8 (dashed line), and pH 2.5 (dotted line) at 25 °C. B, pH dependence of the CD signal at 198 nm (filled circles) and 218 nm (open triangles). Error bars are standard deviations estimated from several independent experiments for both neutral (pH range 6.7-7.3; n = 5) and endosomal pH (pH range 4.7-5.2; n = 4); for the 198-nm signal, the error bar at neutral pH is too small to be visible. Variations in the intensity of the 218-nm peak at pH >= 3.5 were within experimental error, whereas the intensity of the 198-nm peak was reproducibly higher at endosomal pH. As a concentration-independent measure of spectral shape, ratios of the intensities of the 198-nm to the 218-nm peak (= -[theta ]r, 198/[theta ]r, 218) were 0.82 ± 0.06 in the neutral and 1.01 ± 0.03 in the endosomal pH range.

Changes in far-UV CD spectra tend to be dominated by changes in the chiral environment surrounding peptide bonds (54). We wished to investigate whether other aspects of sDM conformation also were influenced by pH. To this end, we used fluorescence spectroscopy, which is highly sensitive to the environment of aromatic residues in proteins, particularly tryptophans and to a lesser extent tyrosines. The sDM molecule has a large number of aromatic residues, including 11 tryptophans, dispersed throughout both the alpha  and beta  chain. Spectral changes between neutral and endosomal pH were readily seen using this technique (Fig. 5A). At pH 7.0, the emission spectrum had a maximum at 338 nm; at pH 5.0, the maximum was reproducibly blue-shifted to 337 nm, and the maximum fluorescence intensity was decreased by about 20%. These results indicated that a majority of tryptophans were buried in native sDM and suggested that their average environment became slightly more nonpolar at endosomal pH. These changes could involve subtle adjustments in the environment of numerous residues or substantial movements of one or a small number of them. The spectral changes were reversible on a time scale of minutes or less (Fig. 5A), implying that the underlying structural changes were rapid and bidirectional. These observations ruled out, for instance, pH-dependent cleavage by contaminating proteases as an explanation for the spectral changes. Both the pH 5 and pH 7 signals were linear between 50 and 1000 nM sDM, indicating that concentration-dependent differences in oligomerization state were not responsible for the spectral differences (data not shown).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Intrinsic tryptophan fluorescence spectra of sDM. A, stocks of sDM were diluted to 250 nM in 20 mM sodium phosphate, pH 7.0 (open triangles), or in 20 mM sodium acetate, pH 5 (open circles). To test for reversibility, sDM was diluted first into pH 5 buffer and then 20-fold into pH 7 buffer (filled triangles) or vice versa (filled circles). Intrinsic tryptophan fluorescence emission spectra were recorded as described under "Materials and Methods." B, fluorescence spectra of sDM at pH 7.0 (triangles) or 5.0 (circles) in the presence (filled symbols) or absence (open symbols) of 6 M guanidinium chloride. C, fluorescence spectra of sDM at pH 7.0 (triangles) or pH 5.0 (circles) with (filled symbols) or without (open symbols) 150 mM NaCl.

To assess the extent to which Trp residues are buried within the folded structure of sDM, we examined spectral changes upon unfolding in the presence of 6 M guanidinium chloride (Fig. 5B). Under these conditions, the emission maximum was red-shifted to 353 nm, and a substantial increase in fluorescence intensity was observed. Given that fully buried Trp residues generally emit maximally at about 330 nm and fully exposed residues at around 350 nm (54), these results confirmed that sDM was substantially folded and indicated that an average Trp (or the majority of Trp residues) in sDM was likely to be shielded from aqueous solvent within the folded structure at both neutral and endosomal pH levels. In contrast to the drastic effects of high denaturant concentrations, addition of 150 mM NaCl had little (if any) effect on the fluorescence spectra (Fig. 5B). This result suggested that the conformational changes measured by far-UV CD in low ionic strength buffers resemble those at more physiological salt concentrations.

The changes seen by both CD and fluorescence spectroscopy between neutral and endosomal pH levels were rather subtle and could have arisen from relatively minor structural perturbations. To obtain additional information on the extent of the pH-dependent changes, the stability of sDM was compared at pH 7 and pH 5. Guanidinium chloride was used to unfold sDM at room temperature, low sDM concentrations were used to avoid aggregation of denatured sDM at pH 5 (data not shown), and unfolding was monitored using intrinsic tryptophan fluorescence at 350 nm (Fig. 6). At both pH 7 and pH 5, unfolding occurred over a narrow range of guanidinium chloride concentrations, with greater stability at pH 7 (half-maximal unfolding at 1.8 M guanidine-HCl) than at pH 5 (1.3 M guanidine-HCl). At both pH values, unfolding was irreversible (data not shown), precluding analysis of unfolding thermodynamics using simple reversible two-state models. Nevertheless, these results confirmed the stability of sDM at both pH 7 and pH 5 in the absence of denaturant and showed that the conformational stability of sDM was somewhat decreased at pH 5. We concluded that the pH-dependent structural change was sufficiently extensive to perturb protein stability.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Influence of pH on the stability of sDM to denaturation by guanidinium chloride. 250 nM sDM was exposed to increasing amounts of guanidinium chloride in 20 mM sodium phosphate (pH 7.0; triangles) or sodium acetate (pH 5.0; circles) buffers and allowed to equilibrate; intrinsic tryptophan fluorescence was measured at 350 nm. A plot of fluorescence intensity versus guanidinium chloride concentration was used to determine the extent of sDM unfolding as described under "Materials and Methods."

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this study, we have used recombinant soluble HLA-DM molecules to explore the secondary structure composition and conformational dynamics of HLA-DM. The choice of analyzing only the lumenal domains as a soluble molecule, rather than full-length material containing the transmembrane and cytoplasmic domains, was based on two considerations. First, it permitted comparisons between our CD spectra and published spectra of a number of soluble derivatives of classical MHC molecules analyzed using similar techniques. Use of soluble molecules also obviated the need for detergent to solubilize transmembrane proteins, which interferes with far-UV CD measurements by UV absorption. Despite the requirement for relatively high concentrations of sDM to observe activity in vitro, there is no detectable difference between the amounts of full-length and soluble DM required to catalyze peptide exchange of soluble DR molecules, implying that the absence of the transmembrane anchor in soluble DM does not cause malfolding. Although it is conceivable that the folding of sDM is heterogeneous, the spectroscopic and stability studies reported here do not show evidence for contamination with denatured material and provide direct evidence for pH-dependent conformational changes. Thus, even though it is difficult to rule out minor structural differences between native and recombinant full-length DM, it is unlikely that the structural and conformational properties of sDM differ substantially from those of the native molecule.

Secondary structure estimates for sDM based on far-UV CD spectra suggest that the alpha -helix and beta -sheet content of sDM are within the range seen for classical and nonclassical MHC class I and classical class II molecules. Substantial helix content likely is limited to the membrane-distal, N-terminal domains that comprise the peptide-binding groove of classical MHC proteins. Both of the C-terminal epitope tags are highly charged, proline-containing sequences that are quite unlikely to form alpha -helices, and the membrane-proximal domains have unambiguous homology to immunoglobulin superfamily domains that are known to lack helices (32). Together with our recent finding that the conserved Cys-79 of the DM beta  chain participates in disulfide bonding (33), the spectroscopic data reported here are consistent with an MHC-like fold. Nevertheless, spectra of representative MHC class I and class II molecules differ significantly from one another, and the sDM spectrum, while being somewhat more class II-like in overall shape, was clearly not superimposable with that of Ek. The spectral differences could be due to minor differences in secondary or tertiary structure or in non-peptide bond contributions. Thus, our results allow for the possibility that the tertiary fold of DM may be different from that of classical MHC molecules in important aspects, for instance with regard to the presence of an antigen-binding groove. A precedent for this possibility has been found upon crystallographic analysis of the rat neonatal Fc receptor (55). The secondary and tertiary structures of this molecule are MHC-like, but the helices that flank the bound antigenic peptide in classical MHC proteins are closely apposed, leaving no room for a ligand.

Previous work has shown differences in binding of the hydrophobic fluorescent dye, anilinonaphthalenesulfonic acid, to sDM at pH 7 and pH 5 (28, 40).2 However, the amounts of protein required to observe substantial dye binding differed 10-fold between the published studies, and the pH effects were relatively small, raising questions about the nature and extent of the conformational change. Our far-UV CD (Fig. 3) and fluorescence spectra (Fig. 5) show that sDM exists in spectroscopically distinguishable, rapidly interconvertible states at pH 7 and pH 5, which are distinct from acid-, chaotrope-, or heat-denatured conformations. These observations could reflect conformational changes or changes in the local dielectric constant near side chains that become protonated at pH 5. That the conformation of sDM does change significantly at endosomal pH is indicated by the observation that the stability of sDM to unfolding by guanidinium chloride is decreased at pH 5. Some destabilization at pH 5 is consistent with the results of experiments using hydrophobic fluorescent dyes that indicate an increased exposure of hydrophobic sites in sDM to solvent at endosomal pH (40). However, the small extent of the pH-dependent changes in the CD and fluorescence spectra indicates that the structural alterations are not drastic; indeed, CD-based secondary structure estimates change minimally, if at all, between pH 7 and pH 5. Clearly, sDM maintains stability and has a long half-life in protease-rich endocytic compartments (7, 33); it therefore must remain sufficiently rigid at endosomal pH to remain resistant to proteolytic attack in acidic peptide loading compartments.

How the pH-dependent conformational change identified by our experiments contributes to improved function of DM at endosomal pH remains unclear. A previous report showed evidence for masking of hydrophobic sites within DM-class II complexes, implicating hydrophobic interactions in maintaining affinity (40). However, the global structural changes indicated by the effect of pH on protein stability and the ability of diverse spectroscopic techniques to detect the conformational change raise the possibility that multiple structural rearrangements in DM contribute to optimal interactions with class II molecules. In addition, previously identified pH-dependent conformational changes in class II molecules may contribute to the interaction (see Introduction). Further work will be needed to evaluate the relative contributions of different types of intermolecular interactions to the ability of DM both to bind class II molecules and to catalyze their peptide exchange reactions.

The reversibility of the conformational change is compatible with models in which DM release from class II molecules is controlled by pH changes, which occur upon recycling between endosomal compartments and the cell surface (35). However, the alternative view that binding of stable peptides causes DM release within endosomes (25, 26) is not ruled out by our data.

In some respects, the conformational dynamics of sDM seem to be intermediate between classical class I and II molecules (cf. Ref. 44). For several classical class II molecules, exposure to endosomal pH causes slight CD changes in the near-UV region (which probes aromatic residues) and even subtler changes in the far-UV region, but no changes in protein stability as measured by thermal unfolding. In contrast, for classical class I proteins, conformational stability tends to be greatly reduced or lost at pH 5; this may be a functional adaptation that prevents aberrant loading of class I molecule recycling through endosomes with exogenous peptides. In our studies, HLA-DM seems to be intermediate with respect to the effect of pH on spectral properties and stability to unfolding. Whereas the conformational dynamics of sDM revealed by our studies may readily be viewed as an adaptation for its function in vivo, it is also possible that the differences between the conformational properties of sDM and classical MHC class I and class II molecules relate to their early divergence in evolution (32).

    ACKNOWLEDGEMENTS

We thank Dr. Mark M. Davis for use of the spectropolarimeter, Dr. Henk Vreman for use of the spectrofluorimeter, and Drs. Mark M. Davis, Harden M. McConnell, and Thomas G. Anderson for critical review of the manuscript.

    FOOTNOTES

* This work was supported by funding from the National Institutes of Health (Grant AI-28809) and the Arthritis Foundation and by the Howard Hughes Medical Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a fellowship from the Arthritis Foundation. To whom correspondence should be addressed: Dept. of Pediatrics, Stanford University Medical Center, 300 Pasteur Dr., Stanford, CA 94305-5208. Tel.: 650-498-7574; Fax: 650-498-6077; E-mail: rbusch{at}leland.stanford.edu.

parallel Present address: Robert Wood Johnson Medical School, New Brunswick, NJ 08903.

The abbreviations used are: MHC, major histocompatibility complex; HLA, human leukocyte antigen; sDM/sDR, recombinant soluble HLA-DM/DR; CD4/8, cluster of differentiation 4/8 antigen; Ii, invariant chain; CLIP, class II-associated invariant chain peptide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; PAGE, polyacrylamide gel electrophoresis; mAb, monoclonal antibody.

2 R. Busch, unpublished observations.

3 D. M. Zaller, R. C. Doebele, and R. Busch, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Germain, R. N. (1994) Cell 76, 287-299[CrossRef][Medline] [Order article via Infotrieve]
  2. Stroynowski, I., and Forman, J. (1995) Curr. Opin. Immunol. 7, 97-102[CrossRef][Medline] [Order article via Infotrieve]
  3. Busch, R., and Mellins, E. D. (1996) Curr. Opin. Immunol. 8, 51-58[CrossRef][Medline] [Order article via Infotrieve]
  4. Jensen, P. E. (1998) Curr. Biol. 8, R128-R131[CrossRef][Medline] [Order article via Infotrieve]
  5. Mellins, E., Smith, L., Arp, B., Cotner, T., Celis, E., and Pious, D. (1990) Nature 343, 71-74[CrossRef][Medline] [Order article via Infotrieve]
  6. Morris, P., Shaman, J., Attaya, M., Amaya, M., Goodman, S., Bergman, C., Monaco, J. J., and Mellins, E. (1994) Nature 368, 551-554[CrossRef][Medline] [Order article via Infotrieve]
  7. Denzin, L. K., Robbins, N. F., Carboy-Newcomb, C., and Cresswell, P. (1994) Immunity 1, 595-606[CrossRef][Medline] [Order article via Infotrieve]
  8. Fling, S. P., Arp, B., and Pious, D. (1994) Nature 368, 554-558[CrossRef][Medline] [Order article via Infotrieve]
  9. Sette, A., Ceman, S., Kubo, R. T., Sakaguchi, K., Appella, E., Hunt, D. F., Davis, T. A., Michel, H., Shabanowitz, J., Rudersdorf, R., et al.. (1992) Science 258, 1801-1804[Abstract/Free Full Text]
  10. Riberdy, J. M., Newcomb, J. R., Surman, M. J., Barbosa, J. A., and Cresswell, P. (1992) Nature 360, 474-477[CrossRef][Medline] [Order article via Infotrieve]
  11. Avva, R. R., and Cresswell, P. (1994) Immunity 1, 763-774[CrossRef][Medline] [Order article via Infotrieve]
  12. Miyazaki, T., Wolf, P., Tourne, S., Waltzinger, C., Dierich, A., Barois, N., Ploegh, H., Benoist, C., and Mathis, D. (1996) Cell 84, 531-541[CrossRef][Medline] [Order article via Infotrieve]
  13. Fung-Leung, W. P., Surh, C. D., Liljedahl, M., Pang, J., Leturcq, D., Peterson, P. A., Webb, S. R., and Karlsson, L. (1996) Science 271, 1278-1281[Abstract]
  14. Martin, W. D., Hicks, G. G., Mendiratta, S. K., Leva, H. I., Ruley, H. E., and Van Kaer, L. (1996) Cell 84, 543-550[CrossRef][Medline] [Order article via Infotrieve]
  15. Sloan, V. S., Cameron, P., Porter, G., Gammon, M., Amaya, M., Mellins, E., and Zaller, D. M. (1995) Nature 375, 802-806[CrossRef][Medline] [Order article via Infotrieve]
  16. Denzin, L. K., and Cresswell, P. (1995) Cell 82, 155-165[CrossRef][Medline] [Order article via Infotrieve]
  17. Sherman, M. A., Weber, D. A., and Jensen, P. E. (1995) Immunity 3, 197-205[CrossRef][Medline] [Order article via Infotrieve]
  18. Van Ham, S. M., Grüneberg, U., Malcherek, G., Bröker, I., Melms, A., and Trowsdale, J. (1996) J. Exp. Med. 184, 2019-2024[Abstract/Free Full Text]
  19. Kropshofer, H., Vogt, A. B., Moldenhauer, G., Hammer, J., Blum, J. S., and Hämmerling, G. J. (1996) EMBO J. 15, 6144-6154[Medline] [Order article via Infotrieve]
  20. Katz, J. F., Stebbins, C., Appella, E., and Sant, A. J. (1996) J. Exp. Med. 184, 1747-1753[Abstract/Free Full Text]
  21. Lightstone, L., Hargreaves, R., Gabriele, B., Peterson, M., Aichinger, G., Lombardi, G., and Lechler, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5772-5777[Abstract/Free Full Text]
  22. Green, J. M., Demars, R., Xu, X. X., and Pierce, S. K. (1995) J. Immunol. 155, 3759-3768[Abstract]
  23. Stang, E., Guerra, C. B., Amaya, M., Paterson, Y., Bakke, O., and Mellins, E. D. (1998) J. Immunol. 160, 4696-4707[Abstract/Free Full Text]
  24. Guerra, C. B., Busch, R., Doebele, R. C., Liu, W., Sawada, T., Kwok, W. W., Chang, M. Y., and Mellins, E. D. (1998) J. Immunol. 160, 4289-4297[Abstract/Free Full Text]
  25. Denzin, L. K., Hammond, C., and Cresswell, P. (1996) J. Exp. Med. 184, 2153-2165[Abstract/Free Full Text]
  26. Kropshofer, H., Arndt, S. O., Moldenhauer, G., Hämmerling, G. J., and Vogt, A. B. (1997) Immunity. 6, 293-302[CrossRef][Medline] [Order article via Infotrieve]
  27. Denzin, L. K., Sant'Angelo, D. B., Hammond, C., Surman, M. J., and Cresswell, P. (1997) Science 278, 106-109[Abstract/Free Full Text]
  28. Liljedahl, M., Winqvist, O., Surh, C. D., Wong, P., Ngo, K., Teyton, L., Peterson, P. A., Brunmark, A., Rudensky, A. Y., Fung-Leung, W.-P., and Karlsson, L. (1998) Immunity 8, 233-243[CrossRef][Medline] [Order article via Infotrieve]
  29. Van Ham, S. M., Tijn, E. P. M., Lillemeier, B. F., Grüneberg, U., Van Meijgaarden, K. E., Pastoors, L., Verwoerd, D., Tulp, A., Canas, B., Rahman, D., Ottenhoff, T. H. M., Pappin, D. J. C., Trowsdale, J., and Neefjes, J. (1997) Curr. Biol. 7, 950-957[CrossRef][Medline] [Order article via Infotrieve]
  30. Radley, E., Alderton, R. P., Kelly, A., Trowsdale, J., and Beck, S. (1994) J. Biol. Chem. 269, 18834-18838[Abstract/Free Full Text]
  31. Kelly, A. P., Monaco, J. J., Cho, S. G., and Trowsdale, J. (1991) Nature 353, 571-573[CrossRef][Medline] [Order article via Infotrieve]
  32. Cho, S. G., Attaya, M., and Monaco, J. J. (1991) Nature 353, 573-576[CrossRef][Medline] [Order article via Infotrieve]
  33. Busch, R., Doebele, R. C., von Scheven, E., Fahrni, J., and Mellins, E. D. (1998) J. Immunol. 160, 734-743[Abstract/Free Full Text]
  34. Kropshofer, H., Hämmerling, G. J., and Vogt, A. B. (1997) Immunol. Today 18, 77-82[CrossRef][Medline] [Order article via Infotrieve]
  35. Sanderson, F., Thomas, C., Neefjes, J., and Trowsdale, J. (1996) Immunity 4, 87-96[CrossRef][Medline] [Order article via Infotrieve]
  36. Vogt, A. B., Kropshofer, H., Moldenhauer, G., and Hämmerling, G. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9724-9729[Abstract/Free Full Text]
  37. Weber, D. A., Evavold, B. D., and Jensen, P. E. (1996) Science 274, 618-620[Abstract/Free Full Text]
  38. Roche, P. A. (1996) Science 274, 526-527[Free Full Text]
  39. Mellins, E., Cameron, P., Amaya, M., Goodman, S., Pious, D., Smith, L., and Arp, B. (1994) J. Exp. Med. 179, 541-549[Abstract/Free Full Text]
  40. Ullrich, H. J., Döring, K., Grüneberg, U., Jähnig, F., Trowsdale, J., and Van Ham, S. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13163-13168[Abstract/Free Full Text]
  41. Fremont, D. H., Hendrickson, W. A., Marrack, P., and Kappler, J. (1996) Science 272, 1001-1004[Abstract]
  42. Runnels, H., Moore, J. C., and Jensen, P. E. (1996) J. Exp. Med. 183, 127-136[Abstract/Free Full Text]
  43. Boniface, J. J., Lyons, D. S., Wettstein, D. A., Allbritton, N. L., and Davis, M. M. (1996) J. Exp. Med. 183, 119-126[Abstract/Free Full Text]
  44. Reich, Z., Altman, J. D., Boniface, J. J., Lyons, D. S., Kozono, H., Ogg, G., Morgan, C., and Davis, M. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2495-2500[Abstract/Free Full Text]
  45. Kropshofer, H., Bohlinger, I., Max, H., and Kalbacher, H. (1991) Biochemistry 30, 9177-9187[CrossRef][Medline] [Order article via Infotrieve]
  46. Gorga, J. C., Horejsi, V., Johnson, D. R., Raghupathy, R., and Strominger, J. L. (1987) J. Biol. Chem. 262, 16087-16094[Abstract/Free Full Text]
  47. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
  48. Edelhoch, H. (1967) Biochemistry 6, 1948-1954[CrossRef][Medline] [Order article via Infotrieve]
  49. Gill, S. C., and von Hippel, P. H. (1989) Anal. Biochem. 182, 319-326[CrossRef][Medline] [Order article via Infotrieve]
  50. Crowley, M. P., Reich, Z., Mavaddat, N., Altman, J. D., and Chien, Y.-h. (1997) J. Exp. Med. 185, 1223-1230[Abstract/Free Full Text]
  51. Andrade, M. A., Chacón, P., Merelo, J. J., and Morán, F. (1993) Prot. Eng. 6, 383-390[Abstract/Free Full Text]
  52. Merelo, J. J., Andrade, M. A., Prieto, A., and Morán, F. (1994) Neurocomputing 6, 443-454[CrossRef]
  53. Gorga, J., Dong, A., Manning, M., Woody, R., Caughey, W., and Strominger, J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2321-2325[Abstract/Free Full Text]
  54. Creighton, T. E. (1993) Proteins: Structures and Molecular Properties, W. H. Freeman & Co., New York
  55. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., and Bjorkman, P. J. (1994) Nature 372, 336-343[CrossRef][Medline] [Order article via Infotrieve]
  56. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C. (1987) Nature 329, 506-512[CrossRef][Medline] [Order article via Infotrieve]
  57. Gastinel, L. N., Simister, N. E., and Bjorkman, P. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 638-642[Abstract/Free Full Text]
  58. Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993) Nature 364, 33-39[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
G. M. Grotenbreg, M. J. Nicholson, K. D. Fowler, K. Wilbuer, L. Octavio, M. Yang, A. K. Chakraborty, H. L. Ploegh, and K. W. Wucherpfennig
Empty Class II Major Histocompatibility Complex Created by Peptide Photolysis Establishes the Role of DM in Peptide Association
J. Biol. Chem., July 20, 2007; 282(29): 21425 - 21436.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. C. Doebele, A. Pashine, W. Liu, D. M. Zaller, M. Belmares, R. Busch, and E. D. Mellins
Point Mutations in or Near the Antigen-Binding Groove of HLA-DR3 Implicate Class II-Associated Invariant Chain Peptide Affinity as a Constraint on MHC Class II Polymorphism
J. Immunol., May 1, 2003; 170(9): 4683 - 4692.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. Rotzschke, J. M. Lau, M. Hofstatter, K. Falk, and J. L. Strominger
A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules
PNAS, December 24, 2002; 99(26): 16946 - 16950.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. P. Belmares, R. Busch, K. W. Wucherpfennig, H. M. McConnell, and E. D. Mellins
Structural Factors Contributing to DM Susceptibility of MHC Class II/Peptide Complexes
J. Immunol., November 1, 2002; 169(9): 5109 - 5117.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. S. Patil, A. Pashine, M. P. Belmares, W. Liu, B. Kaneshiro, J. Rabinowitz, H. McConnell, and E. D. Mellins
Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles
J. Immunol., December 15, 2001; 167(12): 7157 - 7168.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. A. Weber, C. T. Dao, J. Jun, J. L. Wigal, and P. E. Jensen
Transmembrane Domain-Mediated Colocalization of HLA-DM and HLA-DR Is Required for Optimal HLA-DM Catalytic Activity
J. Immunol., November 1, 2001; 167(9): 5167 - 5174.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. A. Zarutskie, R. Busch, Z. Zavala-Ruiz, M. Rushe, E. D. Mellins, and L. J. Stern
The kinetic basis of peptide exchange catalysis by HLA-DM
PNAS, October 12, 2001; (2001) 211439398.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Faubert, A. Samaan, and J. Thibodeau
Functional Analysis of Tryptophans alpha 62 and beta 120 on HLA-DM
J. Biol. Chem., January 18, 2002; 277(4): 2750 - 2755.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. A. Zarutskie, R. Busch, Z. Zavala-Ruiz, M. Rushe, E. D. Mellins, and L. J. Stern
The kinetic basis of peptide exchange catalysis by HLA-DM
PNAS, October 23, 2001; 98(22): 12450 - 12455.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Busch, R.
Right arrow Articles by Mellins, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Busch, R.
Right arrow Articles by Mellins, E. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement